Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 117

  • 1 664 clinical trials
  • 562 recruiting
  • 293 conditions
  • 29 countries

Conditions in this area

293 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma89Dermatitis atopic89HIV infection78Rheumatoid arthritis75Systemic lupus erythematosus63Multiple sclerosis59Psoriasis54Psoriatic arthropathy46Myasthenia gravis44Type 1 diabetes mellitus41Systemic scleroderma40Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Sjogren's syndrome31Cardiac amyloidosis29Interstitial lung disease29Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy24Vitiligo24Hereditary angioedema22Axial spondyloarthritis21+269

Clinical trials in Immune system disorders

1 664 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 664 clinical trials

Conjunctivitis allergic

Not recruiting

Study on the Safety and Effectiveness of Betula Pollen Extract for Children and Adolescents Aged 5-17 with Birch Pollen Allergies and Possible Asthma

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Betula Pollen Extract
  • Sponsor:Stallergenes

Lupus nephritis+1

Not recruiting

Study on Vemircopan for Adults with Lupus Nephritis or IgA Nephropathy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Vemircopan
  • Sponsor:Alexion Pharmaceuticals Inc.

Idiopathic pulmonary fibrosis

Not recruiting

Study on the Effects of Deupirfenidone and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Deupirfenidone
  • Sponsor:Puretech Lyt 100 Inc.

Rheumatoid arthritis

Not recruiting

Study on the Effects of Baricitinib in Early-Stage Rheumatoid Arthritis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Baricitinib
  • Sponsor:Universitaetsklinikum Erlangen AöR

Axial spondyloarthritis

Not recruiting

Study of Secukinumab for Maintaining Remission in Patients with Non-Radiographic Axial Spondyloarthritis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Rheumatoid arthritis

Not recruiting

Study on Monitoring Adalimumab for Maintaining Disease Control in Adults with Rheumatoid Arthritis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Adalimumab
  • Sponsor:Diakonhjemmet Sykehus AS

Rheumatoid arthritis

Not recruiting

Study on the Effects of Folate-Based Liposomes with Methotrexate for Patients with Moderate-to-Severe Rheumatoid Arthritis

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Methotrexate
  • Sponsor:Solfarcos Solucoes Farmaceuticas E Cosmeticas Lda.

Colitis ulcerative+1

Not recruiting

Study on the Effectiveness and Safety of Subcutaneous Infliximab for Patients with Active Crohn's Disease or Ulcerative Colitis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:Centre Medico Chirurgical Ambroise Pare Hartmann

Systemic lupus erythematosus+1

Not recruiting

Study on the Safety and Effects of YTB323, Fludarabine Phosphate, and Tocilizumab in Patients with Severe, Refractory Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Idiopathic pulmonary fibrosis

Not recruiting

Study on Fipaxalparant for Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fipaxalparant
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Colitis ulcerative

Not recruiting

Study on the Effects of Guselkumab and Golimumab for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Graft versus host disease

Not recruiting

Study on the Safety and Effectiveness of Human Alpha1-Proteinase Inhibitor for Preventing Graft-Versus-Host Disease in Patients Undergoing Hematopoietic Cell Transplant.

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Human ALPHA1-PROTEINASE inhibitor
  • Sponsor:CSL Behring LLC

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine40 clinical trialsTenofovir Alafenamide38 clinical trialsTocilizumab38 clinical trialsMethotrexate37 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.